25-27
Aug
2026
CPHI Korea 2026
COEX, Seoul, Korea
Q23
Book a meeting

MFC Co.,Ltd.

About MFC Co.,Ltd.

MFC Co., Ltd., established in 2008, is a manufacturer specializing in APIs and key intermediates, which GMP certified from KMFDS. MFC is continuously developing under quality management through thorough quality control and quality assurance system, and technology management that put best efforts in continuous process improvement and new technology development.

Read more Show less
Certifications
  • GMP
    GMP
  • ISO
    ISO
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Korea 2026

    CPHI Korea 2026

    COEX, Seoul, Korea
    25 Aug 2026 - 27 Aug 2026
  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2022
  • Certificates:
    3
  • Employees:
    50 - 99
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Generic APIs producer
Contact info
  • +82-31-8059-8295
  • 35, Cheongwonsandan 7-gil, Mado-myeo, Hwaseong-si, Gyeonggi-do, Korea, Republic Of
Show contact info Hide contact info

Products from MFC Co.,Ltd. (2)

  • Synthesis of APIs

    Product Synthesis of APIs

    APIs:  Pitavastatin Calcium Hydrate, Rosuvastatin Calcium, Donepezil, Clopidogrel Bisulfate, Sarpogrelate Hydrochloride, Erdosteine, Pelubiprofen, (S)-Amlodipine Besylate 2.5 Hydrate, (S)-Pantoprazole Sodium Trihydrate

    Intermediates of Statins:
    MRV-1, ...
  • TBFA

    Product TBFA

    High purity target compounds in solid phase (amorphous/crystalline form) rather than oil phase.

    Detailed technologies: 1) High-purity synthesis technology 
    2) Separation and purification technology            
    3...

MFC Co.,Ltd. Resources (1)

  • MFC Co.,Ltd

    Video MFC Co.,Ltd

    MFC Co., Ltd., established in 2008, is a manufacturer specializing in APIs and key intermediates, which GMP certified from KMFDS. MFC is continuously developing under quality management through thorough quality control and quality assurance system, and technology management that put best efforts in continuous process improvement and new technology development. MFC's direction and aim are the development of new excellent new APIs and intermediates, CMO/CDMO business in accordance with customer requirements, and Incrementally Modified Drugs (IMD) & New Chemical Entity (NCE) using specialized technologies to go forward as a global pharmaceutical company.
    2024-09-23